because the structure and action of SOD1 were fairly well characterized, and it was hoped that understanding the molecular basis for how the pathogenic SOD1 mutations exert their toxic effects in motor neurons would illuminate novel avenues of therapeutic intervention. In addition, because sALS and fALS are similar clinically, it is possible that the underlying molecular causes for the two forms of the disease could be related and therapeutics effective for SOD1-linked ALS might prove effective for the more prevalent sporadic forms of the disease. Today, nearly 16 years after lesions in the gene encoding SOD1 were first linked to fALS, the number of distinct ALS-SOD1 mutations published in the literature has risen to ;100 (Table 1) (7, 8) . However, an effective treatment has still not yet been identified and acquiring an understanding of the molecular basis for SOD1-linked ALS has proven elusive.
Pathogenic SOD1 Proteins Have Acquired a Toxic Property SOD1 detoxifies reactive superoxide anion, a normal byproduct of cellular respiration, to molecular oxygen and water [2O 2 þ 2H þ ! H 2 O 2 þ O 2 ] (9). In mammals, SOD1 is ubiquitously expressed in all tissues and within cells it is primarily localized to the cytosol, although lesser amounts are found in the nucleus, peroxisomes, and mitochondria (10) . The enzyme is particularly plentiful in the spinal cord and brain, where it has been estimated to comprise between 0.1% and 2.0% of the detergent-soluble protein (11, 12) . This abundance likely reflects the copious superoxide generated by these highly respiring tissues. The fundamental role of SOD1 as an antioxidant protein, combined with its abundance in neural tissue, suggested an initial hypothesis that the pathogenic SOD1 mutations might result in an enzyme that is unable to detoxify reactive oxygen species. Over time, this loss of enzymatic function could lead to oxidative damage and death of neural cells. However, mice lacking SOD1 do not develop motor neuron disease (13) and transgenic mice expressing human fALS SOD1 mutants in addition to their own endogenous SOD1 develop paralytic symptoms strikingly similar to those observed in human patients (14) (15) (16) . Together, these observations imply that pathogenic SOD1 molecules act through the gain of a cytotoxic property and not a loss of function (see below).
Genetics and Models of SOD1-Linked fALS
The human SOD1 gene, located on chromosome 21 (17) , is comprised of 5 exons that are spliced to produce mRNA that, when translated, produces a single species of SOD1 protein. In other words, there is no evidence of alternative splicing to produce functionally distinct SOD1 isoforms. The mature mRNA codes for a protein of 154 amino acids, which is post-translationally modified by removal of the initiating methionine, followed by Nterminal acetylation. The mature protein consists of 153 amino acids, and the numbering system used to identify sites of mutation is based on the amino acid sequence of the mature polypeptide. Missense mutations that cause fALS have been documented at 68 positions in the SOD1 protein (Table 1 and Fig. 1 ). With more than 100 missense mutations at these 68 positions, it is obvious that multiple amino acid substitutions at a given position can cause disease (e.g., Gly93 to Ala, Cys, Asp, Arg, Ser, or Val). In initial studies of SOD1-linked fALS (5, 6) , the evidence indicated that the disease was completely penetrant. However, as the identification of new families led to additional mutations, it has become clear that some are not (see http://alsod.iop.kcl.as.uk), meaning that a given individual inheriting a mutant SOD1 allele may live a normal lifespan, with the disease appearing in the next generation. The most common mutation in North America is a substitution of Val for Ala at position 4 (A4V); this mutation appears to be fully penetrant, producing a disease of relatively short duration.
Across species, the amino acid sequence of SOD1 is highly conserved; 112 of 153 residues are conserved in mammals, with 70 invariant across eukaryotic phyla (18) . Sixty-one of the pathogenic mutations occur at residues conserved in mammals, with 49 occurring at positions that are extremely conserved (18) . To our knowledge, there are no reports in the veterinary literature of spontaneous mutations in SOD1 that are associated with a neuromuscular disorder in domesticated or captive animals. However, it has been demonstrated that transgenic over-expression of the mouse SOD1 protein encoding a mutation associated with human fALS (G86R) induces a neuromuscular disorder remarkably similar to fALS (19) . Apart from the experimental murine models, however, SOD1-linked ALS appears to be a uniquely human disease.
The discovery of mutations in SOD1 as a cause of ALS provided the first opportunity to produce a genetically faithful model of the disease. Transgenic mice that overexpress human SOD1-harboring mutations linked to fALS develop muscle loss and paralysis characteristic of human ALS. Almost all of the published models were built by injecting a 12-kb fragment of human genomic DNA containing all regulatory elements as the transgene vector (20) . Mutant human SOD1 genes that have been introduced into mice include A4V (21), G37R (22) , H46R (23), G85R (15), G93A (16), L126Z (14, 21) , L126del(stop 131) (24), and Gins127TGGG (25) . In addition to the mice, there are two examples of transgenic rats that harbor the human gene [H46R (26) and G93A (27) ]. The mouse model most widely used by ALS researchers is the first model that was developed by Mark Gurney and colleagues (16) . This model expresses the fALS variant SOD1-G93A at very high levels and has a disease onset marked by hindlimb weakness at 3-4 months of age, with death occurring by 4-5 months of age. In general, the phenotypic manifestation of disease in all of the mouse and rat models is similar; limb weakness (usually hindlimb) is the first sign, followed by generalized weakness in all limbs and the trunk. Pathologic features of the disease are among the most faithful of all models of human neurologic disease, including loss of large motor neurons of the spinal cord, robust astrogliosis and microgliosis, and inclusion pathology. Overall, it is widely accepted that the mutant SOD1 mouse models faithfully model human SOD1-linked fALS.
Structural Properties of SOD1
SOD1 is a 32-kDa homodimeric enzyme in which each subunit folds as an 8-stranded Greek key b-barrel, binds one copper and one zinc ion, and contains one intrasubunit disulfide bond (28) . Figure 1A shows the mature wild type holoenzyme [pdb code 2C9V (29) ]. Two lengthy loop elements project from the b-barrel that are important in metal ion binding and the formation of the active site. These are termed the ''zinc loop'' (loop IV, residues 50-83) and the ''electrostatic loop'' (loop VII, residues 121-142). In the mature enzyme, the ''disulfide loop,'' a substructure of loop IV (residues 50-62), is covalently linked to the b-barrel through a disulfide bond between C57 and C146 [for review, see (7) ].
The pathogenic SOD1 mutations are grouped based on their positions in the structure (Fig. 1B) . ''b-barrel mutants'' are isolated from their expression systems with metal content nearly identical to that found for the wild type SOD1 expressed in the same systems, while ''metal binding mutants'' tend to be deficient in copper and/or zinc (30, 31) . Three-dimensional structures are known for b-barrel mutants A4V (32), G37R (33, 34) , H43R (35), G93A (36) , and I113T (32) , and these metal-replete structures reveal only slight perturbations relative to the wild type enzyme. Structures of the metal-binding mutants H46R (37, A monomer of SOD1 is shown in the same orientation as the rightmost subunit in Figure 1A . The a-carbon positions of fALS mutations falling in the b-barrel and in the metal-binding loop elements are shown as green and hot pink spheres, respectively. The a-carbon positions of pathogenic SOD1 mutants for which there are mouse models are shown as yellow spheres.
38), H46R/H48Q double mutant (39), G85R (40), D125H (41) , and S134N (37, 42) have also been determined, and most of these are metal-deficient, which in turn results in conformational disorder of the electrostatic and zinc loop elements. The biophysical properties of these two classes of pathogenic SOD1 mutants are dramatically different in their metal-free, disulfide-reduced (newly translated) forms. In differential scanning calorimetry experiments, nascent bbarrel mutants tend to be substantially destabilized relative to the wild type enzyme, while newly translated metalbinding mutants tend to retain thermal stability similar to the wild type enzyme (43, 44) . The thermal stability of newly translated SOD1 proteins overall is significantly enhanced via posttranslational modification to the mature holoenzyme via the action of its copper chaperone (CCS) (45) (see below).
The mature human SOD1 holoenzyme is a remarkably stable dimer, retaining enzymatic activity at elevated temperatures and in the presence of denaturing agents (46, 47) . Although the stabilizing effects of metal ion binding have long been known, recent studies have also illuminated the importance of the intrasubunit disulfide bond to dimer stability. The dimer interface is formed predominantly by reciprocal interactions of the disulfide loop and b-strand 8 across the molecular two-fold axis ( Fig. 1A) (48) . Protein folding (49) , gel filtration (50) , and analytical ultracentrifugation (48) analyses have revealed that reduction of the disulfide bond in the metal-free protein results in monomerization. As can be inferred from Figure 1A , a reduced disulfide bond will result in enhanced mobility of the disulfide loop, weakening the interactions across the dimer interface (51) .
Soluble Oligomers and Insoluble Aggregates of Mutant SOD1 in fALS
One of the common features of the mouse models of SOD1-linked ALS is the accumulation of insoluble forms of mutant protein as the disease progresses (52) . These insoluble mutant proteins are generally thought of as aggregates [for review, see Murphy R.M., 2002 (53) ] that are composed of assemblies of protein that attain relatively high molecular weight (examples include filamentous aggregates as well as smaller oligomeric structures). The mutant proteins are far more prone to form these assemblies than is normal human SOD1 (52) . Soluble higher-order oligomers of pathogenic SOD1 have also been detected (54) , and it is generally presumed that these are on the pathway to the formation of insoluble aggregates. Whether it is the misfolded pathogenic SOD1 monomers, soluble oligomers, or insoluble aggregates that are the noxious entities in SOD1-linked ALS remains unclear. Importantly, in tissues from diseased mice, a majority of the mutant proteins fractionate to the soluble fraction (52) , meaning that only a portion of the total mutant SOD1 in the tissue ends up in the insoluble aggregate.
In general, pathologic protein aggregates resist dissociation in detergent, and larger oligomers can be separated from smaller soluble species by ultracentrifugation or size exclusion chromatography. Forms of mutant SOD1 that are insoluble in non-ionic detergent have been detected in multiple mouse models including mice that express the following variants: A4V (21), G37R (52), G85R (52), mouse G86R (55), G93A (52), L126Z (14) (Fig. 2) , and Gins127TGGG (25) . Similar aggregates were found in spinal cord tissues of an fALS patient harboring the A4V mutation (52) . Aggregation of the mutant protein does not appear to be entirely secondary to disease processes in tissues because high-level expression of the mutant protein in cultured cells can produce assemblies of mutant protein that are biochemically and biophysically similar to the aggregates formed in tissues (52, 55) .
In pathological examination of tissues from humans or from animal models, aggregates of mutant SOD1 are defined by the formation of macromolecular structures termed inclusion-bodies (Fig. 2) . In human disease, the availability of autopsy cases from SOD1-linked cases has been limited, but there are a number of case reports in the literature. The most consistently reported pathologic structures are hyaline or Lewy-body like inclusions that are immunoreactive to SOD1 antibodies; mutants examined include A4V (56, 57); H46R (58); I113T (59); G72C (60); L126del (stop 131) (57, 61); and L126S (62) . However, there have been reports of SOD1-linked ALS cases in which inclusion pathology was either absent or the inclusions that were unreactive with antibodies to SOD1 (56, (63) (64) (65) (66) . In the fALS mouse models, pathologic inclusions are not necessarily prominent pathologic features (14, 16, 22, 52) , but have been observed as the major pathology of mice that express human SOD1-G85R (15) .
The biophysical mechanisms of mutant SOD1 oligomerization/aggregation remain unclear. A number of recent studies provided evidence that aberrant intermolecular disulfide bonding of mutant SOD1 (cysteines at residues 6, 57, 111, 146) either promoted aggregation and/or stabilized aggregates generated by other mechanisms (18, (67) (68) (69) (70) (71) (72) . However, there have been reports of fALS mutations at all four cysteines residues in SOD1 (Table  1) ; recent studies demonstrated that SOD1 mutants encoding disease-linked mutations at these cysteine residues (e.g., C6G, C6F, C111Y, C146R) rapidly formed aggregates when expressed in cell culture (55, 69) . Moreover, Karch and Borchelt demonstrated that experimental mutants that lack all four cysteine residues (C6F/C57S/C111Y/C146R), or which encode only a single cysteine at positions 6 or 111 (C6/C57S/C111Y/C146R or C6F/C57S/C111/C146R) rapidly aggregate when expressed in cultured cells (55) . Recent in vitro studies by Chattopadhyay and colleagues (73) have demonstrated the aggregation of wild-type human SOD1 into amyloid-fibril-like structures via mechanisms that do not appear to involve intermolecular disulfide crosslinking. Collectively, these data suggest that extensive disulfide cross-linking is not required to either promote or stabilize mutant SOD1 oligomerization/aggregation.
Little is known of the structures of mutant SOD1 aggregates that form in vivo. In vitro, metal-depleted mutant forms of SOD1 can assemble into linear and helical filamentous arrays, based on the principle that their b-sheet edges have lost protection from the ''negative design'' inherent in the wild type enzyme (37, 74) . The helical filamentous arrays of metal-depleted pathogenic SOD1 ( Fig.  3 ) (37) have some similarity to the ''amyloid pores'' that have been observed in other neurodegenerative diseases in which protein aggregation is a characteristic feature (75) . In most, but not all fALS mouse models, there is evidence of the accumulation of amyloid-like material; thioflavin-S positive structures (14, 52) . As mentioned above, recent studies by Chattopadhyay and colleagues generated amy-loid-like fibrils of wild-type human SOD1 in vitro. Overall, these studies indicate that SOD1 possesses structural features that impart an inherent propensity to oligomerize/ aggregate; however, the precise nature of the higher order SOD1 species that form in vivo either early or late in disease remains poorly defined. Moreover, we lack a sufficient understanding of the role of specific SOD1 higher-order structures in disease pathogenesis to predict whether disruption of mutant SOD1 oligomerization/aggregation would be beneficial or detrimental. A recent study of forms of SOD1 engineered to produce stable dimeric enzyme suggested toxicity is not tied to aggregation (76) . However, data from cell culture models suggest that formation of large SOD1 aggregates could be a primary mechanism of toxicity (77), although it remains possible that it is the soluble precursors of these large SOD1 aggregates and not the aggregates themselves that are toxic. 
The Copper Chaperone for SOD1 (CCS)
Human CCS is a three-domain polypeptide that confers at least two critical stabilizing posttranslational modifications on newly synthesized SOD1: (i) the insertion of the catalytic copper ion (45) , and (ii) the oxidation of the disulfide bond found within each SOD1 subunit (78) . The presence of a disulfide bond is rare for cytosolic proteins given the strong reducing environment of the cytosol, and recent studies suggest that CCS-mediated oxidation of this disulfide bond occurs concomitant with copper delivery in an oxygen-or superoxide-dependent fashion (78) . It is important to note that at the protein level, the ratio of SOD1 to CCS in the cytosol is estimated to be between 15:1 and 30:1 (79) , meaning that CCS must cycle through the newly translated SOD1 pool to activate these molecules (68) . It is presumed that upon copper delivery to SOD1, CCS becomes recharged with copper via the membrane-bound copper transporter CTR1, although to our knowledge, direct protein-protein interactions between CCS and CTR1 have not yet been demonstrated.
CCS domain I (residues 1-84) contains a copperbinding motif MXCXXC that is postulated to acquire copper ion from the membrane copper transporter CTR1 (68) . Domain II (residues 85-233) is similar to human SOD1 and retains amino acid residues found at the SOD1 dimer interface (80) . Because dimer interface residues are conserved, domain II is proposed to be responsible for the specificity of CCS/SOD1 interaction via the formation of a SOD1/CCS heterodimer (81) . Domain III (residues 234-273) contains the copper-binding motif CXC, which is proposed to directly insert copper ion into nascent SOD1 (81) . The ''heterodimerization'' model of CCS activation of SOD1 ( Fig. 4) has endured for the last decade, although the spatial-temporal mechanistic details of the activation process have remained elusive. Human CCS itself dimerizes though its SOD1-like domain II, which contains a zinc binding site and disulfide bond analogous to those found in SOD1. Unanswered mechanistic questions include: How does CCS reorganize itself to utilize domain II as a nascent SOD1 recognition module? What conformational changes accompany the transfer of copper from CCS domain I to CCS domain III prior to delivery to SOD1? What amino acid residues of both proteins participate in copper delivery and disulfide bond oxidation? Perhaps most importantly, how might fALS mutations in SOD1 interfere with CCS action, and what are the properties of the resulting immature SOD1 proteins (see below)?
An Alternate Model of CCS Action
To probe various mechanistic aspects of CCS action, Blackburn and colleagues titrated purified human CCS with increasing concentrations of Cu(I) followed by EXAFS and gel filtration studies (82) . Upon addition of a single equivalent of Cu(I) per CCS molecule, they observed that the ''canonical'' CCS dimer mediated by the SOD1-like domain II dissociated into monomers and that addition of additional equivalents resulted in the appearance of a ''noncanonical'' dimer mediated by a Cu 4 S 6 copper cluster formed in part by the two CXC motifs of CCS domain III (Fig. 5 ). This canonical-to-noncanonical CCS dimer transition, if it occurs in vivo, would seem to act as a functional copper-sensing switch to make CCS domain II available to nascent SOD1 binding only when sufficient copper is available (82) . Interestingly, a non-canonical domain III mediated CCS dimer similar to that shown in Figure 5 was also observed in the crystal structure of a yeast SOD1/yeast CCS complex, although no copper was present in the crystallization experiment (83) . Taken together, these observations suggest an alternate model of CCS action shown in Figure 6 . However, this new model has not been unambiguously validated and does not reveal precise mechanistic details of the posttranslational modification of SOD1 or how the binding of a single copper ion results in allosteric CCS dimer dissociation (82) . The latter mechanism is particularly intriguing, given that CCS contains its own intrasubunit disulfide bond and bound zinc, which as described above, are both factors that are known to stabilize SOD1 dimers (48) and by extension, would be expected to stabilize CCS dimers.
Immature Pathogenic SOD1 and Toxicity
We suspect that pathogenic SOD1 mutations may result in increased levels of immature SOD1 folding intermediates by hindering the action of CCS at various points in the SOD1 maturation cycle (Fig. 6 ). These immature SOD1 folding intermediates may lack some or all posttranslational modifications that are dependent upon CCS activity, including the insertion of copper co-factors and oxidation of the intrasubunit disulfide bond. Two recent in vitro studies indicate that failure to form the intrasubunit disulfide bond may be a key step (73, 84) . Similarly, studies of aggregates isolated from cell culture and transgenic mouse models indicate that immature SOD1 molecules eventually end up in the insoluble inclusions (85) .
One possible explanation for these observations is that mutant forms of SOD1 interact with CCS in a manner that inhibits normal posttranslational modifications (for example, the nascent metal-binding mutants). Alternatively, some mutant forms may be so destabilized that CCS encounters only a fraction of these variants before they exit the soluble fraction or are turned over by the protein quality control machinery (for example, the nascent b-barrel mutants). Indeed, some mutants, for example, the nascent L126 truncation variant, are so unstable that they would have little chance of normal interaction with CCS. Indeed, CCS would likely fail to bind to and stabilize the nascent L126 molecules it does encounter because the latter molecule is completely lacking a b-strand necessary for wild type SOD1 heterodimerization with CCS domain II. Although the nascent b-barrel mutants such as A4V, G37R, and G93A (among many others) are not quite as radically destabilized as L126Z, they remain significantly thermally destabilized relative to the nascent wild type enzyme (43, 44) . As mentioned previously, because the SOD1:CCS ratio is between 15 and 30:1, we speculate that CCS is unable to cycle through the entire pool of these nascent SOD1 pathogenic mutants before they are degraded, oligomerize, or enter the insoluble fraction.
Metal binding mutants such as H46R, H48Q, H46R/ H48Q, H80R, and D124V (among others), are not destabilized relative to the nascent wild type enzyme, but CCS is unable to convert these molecules to their mature forms via posttranslational modification because these mutations directly prevent metal binding. A recent study on the double copper-binding site mutant H46R/H48Q SOD1 revealed that this pathogenic variant forms quite stable 1:1 complexes with CCS that do not dissociate in analytical gel filtration, analytical ultracentrifugation, and native gel shift experiments (86) , suggesting that this nonproductive SOD1:CCS complex may hinder CCS cycling through the newly translated pool of SOD1 molecules. Finally, CCS would be unable to fully stabilize the pathogenic SOD1 mutants C57R and C146R, which are incapable of forming the intrasubunit disulfide bond.
The notion that soluble immature pathogenic SOD1 molecules may be the noxious species in SOD1-linked fALS is supported by recent studies from the Culotta and Elliott laboratories. Over-expression of CCS was observed to greatly accelerate disease in a G93A SOD1 mouse model in the absence of visible proteinaceous inclusions (87) . Surprisingly, CCS over-expression failed to enhance oxidation of the G93A SOD1 disulfide bond, and in fact, the population of disulfide-reduced G93A SOD1 in the soluble fraction of brain and spinal cord of these animals was elevated (88). In addition, CCS over-expression did not result in a larger fraction of active G93A SOD1 in these animals, suggesting that the SOD1 proteins also remain at least partially metal deficient (88) . In this murine model of ALS, there appears to be augmentation of the mitochondrial pathology that is inherent in the G93A mice, but is not found in several other models (e.g., H46R/H48Q, G85R, L126Z, and G127insTGGG). These data suggest that CCS may be interacting with nascent G93A (these proteins are at an approximate stoichiometric ratio of 1:1 in these animals), preventing it from forming insoluble aggregates, but at the 4) Zinc is loaded into SOD1 (this could also occur as early as step 1). (5-7) Cu(I) from the Cu 4 S 6 cluster is transferred to nascent SOD1 and the intrasubunit disulfide bond in nascent SOD1 is oxidized (68) . Upon being depleted with Cu(I), CCS reforms the canonical CCS dimer and the cycle repeats. The pathogenic SOD1 mutations listed in Table 1 may interfere with CCS-mediated SOD1 maturation at the various positions indicated. The numbers of the pathogenic SOD1 mutants in the blue boxes correspond to their numbers in Table 1. same time, failing to impart the stabilizing posttranslational modifications that transform the nascent SOD1 protein into the enormously stable, mature holoenzyme. It appears that the observed elevated levels of soluble, copper-depleted, disulfide-reduced G93A SOD1 augments the mitochondrial pathology, resulting in significantly earlier onset of paralytic symptoms in these animals. However, it remains unclear why CCS over-expression results in elevated levels of disulfide-reduced G93A SOD1, and additional studies aimed at understanding this phenomenon are needed.
Conclusions
More than 100 mutations in SOD1 have been identified as causing fALS. The precise role of mutant SOD1 oligomerization/aggregation in disease pathogenesis remains uncertain, although there is little dispute that insoluble aggregates of mutant SOD1 are found in all of the transgenic mouse models that have been generated thus far, except in one model where CCS is also over-expressed. Ultimately, the role of mutant SOD1 aggregation in disease may not be established until therapeutic compounds that specifically target mutant SOD1 aggregation are tested in clinical applications. We suggest a potential mechanism of toxicity involving reduced ability of the mutant proteins to interact properly with CCS, which mediates critical posttranslational modification of the SOD1 as it folds into a stable dimeric enzyme. The resulting immature pathogenic SOD1 proteins are essentially folding intermediates that exert their toxic effects through their aggregated or soluble forms, or both.
